Form 4: Enliven Therapeutics CFO Benjamin Hohl Exercises Options and Sells Shares

Enliven Therapeutics CFO Benjamin Hohl executed option exercises and subsequent share sales under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 29, 2024, Benjamin Hohl, CFO of Enliven Therapeutics, exercised options to purchase 5,250 shares of common stock at a price of $2.48 per share.
• Following the exercise, Hohl sold 5,189 shares at a weighted average price of $26.6676 and 61 shares at a weighted average price of $27.4431.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• After these transactions, Hohl directly owns 0 shares of Enliven Therapeutics.
• Hohl also holds 204,370 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates any significant concerns.

Key Dates